Closed Loop Glucose Control in Patients With Type 2 Diabetes

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Ideal Medical Technologies
Study ID
NCT05386849
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • FUSION closed loop glucose control system — DEVICE
    The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.

Study Details

This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting. The type 2 diabetic subjects in this study will have their glucose controlled to a range of 100-140 mg/dL by a novel artificial intelligence based closed loop glucose control system for a period of 24 hours. The subjects will consume three standardized meals during the 24 hour study period.

Key Dates

Start date
May 9, 2022
Status verified
Mar 2026
Primary completion
Jul 19, 2022
Completion
Jul 19, 2022

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY

Arms

  • Experimental: FUSION closed loop glucose control system
    All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours

Primary Outcome Measure

Percent of All Glucose Values Within Glucose Range < 70 mg/dL [ Time Frame: From beginning of use of the FUSION system to end of use of the FUSION system, which will be a period of time of up to 24 hours ]

Locations (1)

FacilityCityStateZIPSite coordinators
Emory UniversityAtlantaGeorgia30322-

Find similar trials in Atlanta, GA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Emory University· Atlanta, GA

Related Studies